European Union - English - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic acid - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile and liver therapy - chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

Israel - English - Ministry of Health

mbi pharma ltd., israel - chenodeoxycholic acid - hard capsule - chenodeoxycholic acid 250 mg - chenodeoxycholic acid - the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - chenodeoxycholic acid - capsule - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - chenodeoxycholic acid - tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

leadiant biosciences ltd - chenodeoxycholic acid - capsule - 250mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule - excipient ingredients: titanium dioxide; maize starch; silicon dioxide; gelatin; magnesium stearate - ursodeoxycholic acid is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: magnesium stearate; colloidal anhydrous silica; maize starch; titanium dioxide; iron oxide yellow; gelatin - ursodox gh (ursodeoxycholic acid) capsule is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; purified talc; polysorbate 80; hypromellose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; macrogol 6000 - treatment of chronic cholestatic liver diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: benzoic acid; glycerol; citric acid; sodium chloride; purified water; sodium citrate dihydrate; propylene glycol; xylitol; sodium cyclamate; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: purified water; sodium cyclamate; citric acid; sodium citrate dihydrate; xylitol; sodium chloride; glycerol; propylene glycol; benzoic acid; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.